Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib

Jared Weiss, Brian Kavanagh, Allison Deal, Liza Villaruz, James Stevenson, Ross Camidge, Hossein Borghaei, Jack West, Padmini Kirpalani, David Morris, Carrie Lee, Chad V. Pecot, Timothy Zagar, Thomas Stinchcombe, Nathan Pennell

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

Introduction: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied. Materials and methods: We treated 25 patients with EGFR mutant NSCLC on erlotinib who had 3 or fewer sites of extra-cranial progression with SRT to progressing sites, followed by re-initiation of erlotinib. Results: Median PFS from the initiation of SRT was 6 months (95% CI 2.5 to 11.6) and median OS was 29 months (95% CI 21.7 to 36.3). Neither baseline nor changes in the Veristrat proteomic predicted PFS. Conclusions: SRT and TKI continuation may be considered for select patients with EGFR mutant NSCLC and oligo-progression on EGFR TKI therapy.

Original languageEnglish
Article number100126
Pages (from-to)100126
JournalCancer Treatment and Research Communications
Volume19
DOIs
StatePublished - Jan 1 2019

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms/secondary
  • Brain Neoplasms/secondary
  • Carcinoma, Non-Small-Cell Lung/pathology
  • Combined Modality Therapy
  • Disease Progression
  • ErbB Receptors/antagonists & inhibitors
  • Erlotinib Hydrochloride/therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Neoplasms/secondary
  • Lung Neoplasms/secondary
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Mutation
  • Prognosis
  • Protein Kinase Inhibitors/therapeutic use
  • Radiosurgery/methods
  • Survival Rate

Fingerprint

Dive into the research topics of 'Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib'. Together they form a unique fingerprint.

Cite this